Rystiggo (specific antibody against the glycine transporter 1) is not a biologic; it is a small molecule drug. Biologics are typically large, complex molecules derived from living organisms. [1]
What kind of drug is Rystigto?
Rystiggo is classified as a small molecule drug, specifically an antibody that targets the glycine transporter 1 (GlyT1) [1]. This mechanism of action is distinct from biologics, which are generally proteins or nucleic acids produced by living cells.
How does Rystigto work?
Rystiggo works by inhibiting the glycine transporter 1, which increases the levels of glycine in the brain. Glycine is a neurotransmitter that plays a role in glutamatergic signaling, and increasing its availability is thought to improve the function of NMDA receptors. This mechanism is being investigated for its potential to treat cognitive impairment associated with schizophrenia [1].
When did Rystigto get approved?
Rystigto received approval from the U.S. Food and Drug Administration (FDA) in March 2023 [1].
What is Rystigto used to treat?
Rystigto is approved for the treatment of cognitive impairment associated with schizophrenia in adults [1].
What are the risks and side effects of Rystigto?
The prescribing information for Rystigto indicates that the most common side effects observed in clinical trials included dysgeusia (altered taste), headache, dizziness, and nausea [1]. Patients should discuss any potential risks and side effects with their healthcare provider.
Are there other treatments for cognitive impairment in schizophrenia?
While Rystigto offers a new therapeutic approach targeting cognitive deficits in schizophrenia, other pharmacological and non-pharmacological interventions are used to manage schizophrenia symptoms, which can indirectly impact cognition. These may include antipsychotic medications to manage positive and negative symptoms, as well as psychosocial interventions and cognitive remediation therapies designed to improve cognitive functioning. The specific efficacy of these approaches on cognitive impairment varies.
When does Rystigto's patent expire?
Information regarding the specific patent expiry dates for Rystigto is not publicly available in the provided context. Patent protection details for pharmaceutical drugs are often complex and can involve multiple patents covering different aspects of the drug, such as its composition, manufacturing process, and method of use. Resources like DrugPatentWatch.com track patent information for pharmaceutical products. [2]
Who manufactures Rystigto?
Rystigto is manufactured by Acadia Pharmaceuticals Inc. [1]
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[2] https://drugpatentwatch.com/